Comments on: Fangda Partners Assisted Qyuns Therapeutics in Reaching a Global Exclusive License Agreement with Roche for Long-acting Autoimmune Bispecific Antibody QX031N

Comments on: Fangda Partners Assisted Qyuns Therapeutics in Reaching a Global Exclusive License Agreement with Roche for Long-acting Autoimmune Bispecific Antibody QX031N /press-release/fangda-partners-qyuns-therapeutics-qx031n/ Thu, 06 Nov 2025 09:28:28 +0000 hourly 1